fda compounding semaglutide enforcement october 2025 news New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Maybe i’m not against compounding
Description
In the assessment of semaglutides safety profile from the studies included in the final analysis, adverse events primarily related to gastrointestinal symptoms were observed as most common, along with other side effects
[DOI] [PMC free article] [PubMed] [Google Scholar] 151.Goodwin P.J., Chen B.E., Gelmon K.A., Whelan T.J., Ennis M., Lemieux J., Ligibel J.A., Hershman D.L., Mayer I.A., Hobday T.J., et al
The question is not "how do I prevent tirzepatide from wearing off?" The question is "how do I manage the first four weeks while steady state builds ?" Those are very different questions with very different answers
How does tirzepatide reconstitution compare to semaglutide reconstitution
No injury is too catastrophic or case too complex for our lawyers
